ProShare Advisors’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $270K | Sell |
17,803
-2,017
| -10% | -$30.5K | ﹤0.01% | 1487 |
|
|
2026
Q1 | $216K | Sell |
19,820
-3,673
| -16% | -$45.9K | ﹤0.01% | 1527 |
|
|
2025
Q4 | $304K | Buy |
23,493
+2,136
| +10% | +$27.4K | ﹤0.01% | 1450 |
|
|
2025
Q3 | $276K | Sell |
21,357
-3,641
| -15% | -$48.6K | ﹤0.01% | 1488 |
|
|
2025
Q2 | $445K | Sell |
24,998
-3,015
| -11% | -$52.5K | ﹤0.01% | 1184 |
|
|
2025
Q1 | $499K | Sell |
28,013
-7,102
| -20% | -$161K | ﹤0.01% | 1101 |
|
|
2024
Q4 | $1.05M | Buy |
35,115
+8,596
| +32% | +$182K | ﹤0.01% | 888 |
|
|
2024
Q3 | $414K | Buy |
+26,519
| New | +$481K | ﹤0.01% | 1258 |
|
|
2023
Q3 | – | Sell |
-6,872
| Closed | -$285K | – | 1850 |
|
|
2023
Q2 | $285K | Sell |
6,872
-439
| -6% | -$27.3K | ﹤0.01% | 1307 |
|
|
2023
Q1 | $440K | Sell |
7,311
-2,738
| -27% | -$219K | ﹤0.01% | 965 |
|
|
2022
Q4 | $737K | Sell |
10,049
-195
| -2% | -$14.7K | ﹤0.01% | 812 |
|
|
2022
Q3 | $778K | Buy |
10,244
+625
| +6% | +$48.8K | ﹤0.01% | 778 |
|
|
2022
Q2 | $668K | Sell |
9,619
-3,227
| -25% | -$243K | ﹤0.01% | 850 |
|
|
2022
Q1 | $1.06M | Sell |
12,846
-4,017
| -24% | -$296K | ﹤0.01% | 897 |
|
|
2021
Q4 | $1.27M | Buy |
16,863
+14,755
| +700% | +$1.48M | ﹤0.01% | 917 |
|
|
2021
Q3 | $245K | Sell |
2,108
-995
| -32% | -$150K | ﹤0.01% | 1685 |
|
|
2021
Q2 | $688K | Buy |
3,103
+1,506
| +94% | +$293K | ﹤0.01% | 1285 |
|
|
2021
Q1 | $211K | Buy |
1,597
+79
| +5% | +$12.5K | ﹤0.01% | 2010 |
|
|
2020
Q4 | $263K | Sell |
1,518
-16,215
| -91% | -$2.22M | ﹤0.01% | 1697 |
|
|
2020
Q3 | $1.97M | Buy |
17,733
+1,683
| +10% | +$135K | 0.01% | 573 |
|
|
2020
Q2 | $952K | Sell |
16,050
-2,654
| -14% | -$175K | 0.01% | 728 |
|
|
2020
Q1 | $1.26M | Sell |
18,704
-14,475
| -44% | -$1.14M | 0.01% | 556 |
|
|
2019
Q4 | $2.8M | Sell |
33,179
-3,293
| -9% | -$266K | 0.01% | 545 |
|
|
2019
Q3 | $2.73M | Buy |
36,472
+728
| +2% | +$58.2K | 0.02% | 528 |
|
|
2019
Q2 | $2.26M | Sell |
35,744
-4,527
| -11% | -$229K | 0.01% | 560 |
|
|
2019
Q1 | $1.94M | Buy |
40,271
+981
| +2% | +$47.2K | 0.01% | 607 |
|
|
2018
Q4 | $1.31M | Sell |
39,290
-7,597
| -16% | -$278K | 0.01% | 653 |
|
|
2018
Q3 | $2.46M | Sell |
46,887
-695
| -1% | -$27.7K | 0.02% | 562 |
|
|
2018
Q2 | $1.49M | Sell |
47,582
-1,460
| -3% | -$40.6K | 0.01% | 691 |
|
|
2018
Q1 | $1.07M | Sell |
49,042
-7,676
| -14% | -$165K | 0.01% | 796 |
|
|
2017
Q4 | $1.15M | Buy |
56,718
+2,620
| +5% | +$50.5K | 0.01% | 775 |
|
|
2017
Q3 | $1.07M | Buy |
54,098
+3,747
| +7% | +$73.6K | 0.01% | 715 |
|
|
2017
Q2 | $871K | Sell |
50,351
-1,954
| -4% | -$25.2K | 0.01% | 768 |
|
|
2017
Q1 | $424K | Sell |
52,305
-13,162
| -20% | -$95K | ﹤0.01% | 1075 |
|
|
2016
Q4 | $514K | Buy |
+65,467
| New | +$527K | 0.01% | 1060 |
|
Other funds holding NVCR
SCM
QCM
ProShare Advisors's NVCR Position: Q2 2026 in Review
ProShare Advisors reduced its NovoCure (NVCR) stake by 10% in Q2 2026, selling an estimated $30.5K and leaving 17,803 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #1487.
ProShare Advisors first reported a position in NVCR in Q4 2016 and has held it in 35 quarters since. The position peaked at $2.8M in Q4 2019. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- ProShare Advisors held 17,803 shares of NovoCure worth $270K as of Q2 2026.
- ProShare Advisors sold 2,017 NovoCure shares in Q2 2026, an estimated $30.5K.
- NovoCure made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1487 holding.
- ProShare Advisors first reported a position in NovoCure in Q4 2016 and has held it in 35 quarters since.
- ProShare Advisors's NovoCure position peaked at $2.8M in Q4 2019.
- 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.